This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2019 Mar 1;125(5):666-669.

doi: 10.1002/cncr.31774. Epub 2019 Jan 29.

Choice of first-line therapy in metastatic melanoma

Geoffrey T Gibney¹, Michael B Atkins¹

Affiliations

PMID: 30695110
DOI: 10.1002/cncr.31774

Free article

Choice of first-line therapy in metastatic melanoma

Geoffrey T Gibney et al. Cancer. 2019.

Free article

. 2019 Mar 1;125(5):666-669.

doi: 10.1002/cncr.31774. Epub 2019 Jan 29.

Authors

Geoffrey T Gibney¹, Michael B Atkins¹

Affiliation

¹ Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC.

PMID: 30695110
DOI: 10.1002/cncr.31774

No abstract available

PubMed Disclaimer

Similar articles

Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
Long G. Long G. Clin Adv Hematol Oncol. 2018 Jan;16(1):25-27. Clin Adv Hematol Oncol. 2018. PMID: 29741501 No abstract available.
Research progress in advanced melanoma.
Luo C, Shen J. Luo C, et al. Cancer Lett. 2017 Jul 1;397:120-126. doi: 10.1016/j.canlet.2017.03.037. Epub 2017 Apr 4. Cancer Lett. 2017. PMID: 28385603 Review.
What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?
Atkins MB. Atkins MB. Clin Adv Hematol Oncol. 2016 Jun;14(6):417-9. Clin Adv Hematol Oncol. 2016. PMID: 27379810 No abstract available.
The benefits of immunotherapy combinations.
Schmidt C. Schmidt C. Nature. 2017 Dec 21;552(7685):S67-S69. doi: 10.1038/d41586-017-08702-7. Nature. 2017. PMID: 29293245 No abstract available.
Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Warner AB, Postow MA. Warner AB, et al. Oncology (Williston Park). 2018 May 15;32(5):228-34. Oncology (Williston Park). 2018. PMID: 29847853 Review.

See all similar articles

Cited by

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.
Rogala P, Czarnecka AM, Cybulska-Stopa B, Ostaszewski K, Piejko K, Ziętek M, Dziura R, Rutkowska E, Galus Ł, Kempa-Kamińska N, Seredyńska J, Bal W, Kozak K, Surus-Hyla A, Kubiatowski T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Rutkowski P. Rogala P, et al. Cancers (Basel). 2022 Apr 24;14(9):2123. doi: 10.3390/cancers14092123. Cancers (Basel). 2022. PMID: 35565255 Free PMC article.
Molecular hydrogen as a potential mediator of the antitumor effect of inulin consumption.
Pascal-Moussellard V, Alcaraz JP, Tanguy S, Salomez-Ihl C, Cinquin P, Boucher F, Boucher E. Pascal-Moussellard V, et al. Sci Rep. 2025 Apr 3;15(1):11482. doi: 10.1038/s41598-025-96346-3. Sci Rep. 2025. PMID: 40181080 Free PMC article.
Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma.
Barnaba N, LaRocque JR. Barnaba N, et al. Cell Cycle. 2021 Jun;20(11):1041-1051. doi: 10.1080/15384101.2021.1922806. Epub 2021 May 9. Cell Cycle. 2021. PMID: 33966611 Free PMC article. Review.
Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III-IV Melanoma: A Systematic Review and Meta-Analysis.
Liu Y, Zhang X, Wang G, Cui X. Liu Y, et al. Front Oncol. 2021 Jun 14;11:693655. doi: 10.3389/fonc.2021.693655. eCollection 2021. Front Oncol. 2021. PMID: 34195094 Free PMC article.
Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model.
Qin SS, Han BJ, Williams A, Jackson KM, Jewell R, Chacon AC, Lord EM, Linehan DC, Kim M, Reuben A, Gerber SA, Prieto PA. Qin SS, et al. Cancers (Basel). 2021 May 11;13(10):2293. doi: 10.3390/cancers13102293. Cancers (Basel). 2021. PMID: 34064795 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information